Minimally Invasive Surgery Helps Young Cancer Patients Maintain Fertility

October 18, 2013

COLUMBUS, Ohio – Although the human papillomavirus (HPV) vaccine, pap smears and increased public awareness have reduced cervical cancer rates in the United States, the disease still affects at least 13,000 women annually—many of them in their child-bearing years.

“The average age of cervical cancer patients is in the early 40s, so many women are younger than that and may not have started their families yet,” says Jeffrey Fowler, MD, a gynecologic oncologist with The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital & Richard J. Solove Research Institute (OSUCCC-James). “In recent years, we’ve often found ourselves treating the cervical cancer while also working to preserve a patient’s ability to conceive.”

In the past, women diagnosed with cervical cancer had two primary treatment options: a radical hysterectomy—removing the uterus, cervix and part of the vagina—or radiation therapy to the pelvis. Both treatment options eliminated a woman’s ability to become pregnant.

The OSUCCC-James gynecologic oncology team offers a minimally invasive procedure known as a radical trachelectomy to preserve a woman’s ability to conceive post treatment. Unlike traditional hysterectomies, the procedure only requires a fraction of the woman’s reproductive tract tissue be removed, preserving her ability to get pregnant after surgery.
Fowler estimates that about 70 percent of the women who have had this procedure nationwide and then attempted to become pregnant have been successful. The procedure is only appropriate for certain women with early stage, localized disease.
“Fertility just wasn’t a consideration in the past. Introduction of the radical tracheloectomy technique has changed that concept,” adds Fowler. “For women who qualify for the procedure, it can be the best of both worlds, and that’s what we aiming for: cancer eradication and enhanced quality of life.”

More Information
For more information about gynecologic oncology care and clinical trials at The OSUCCC-James, call 614-293-5066 or toll-free at 1-800-293-5066 or visit


About the OSUCCC-James
The Ohio State University Comprehensive Cancer Center—Arthur G. James Cancer Hospital and Richard J. Solove Research Institute strives to create a cancer-free world by integrating scientific research with excellence in education and patient-centered care, a strategy that leads to better methods of prevention, detection and treatment. Ohio State is one of only 41 National Cancer Institute (NCI)-designated Comprehensive Cancer Centers and one of only four centers funded by the NCI to conduct both phase I and phase II clinical trials. The NCI recently rated Ohio State’s cancer program as “exceptional,” the highest rating given by NCI survey teams. As the cancer program’s 228-bed adult patient-care component, The James is a “Top Hospital” as named by the Leapfrog Group and one of the top cancer hospitals in the nation as ranked by U.S.News & World Report.

Media Contact:
Amanda Harper, Director of Media Relations, 614-293-3737 or

Contact Media Staff

Amanda Harper

Director of Media Relations

614-685-5420 (direct)

614-293-3737 (main)

Media staff are available by calling 614-293-3737 Monday through Friday between 8 a.m. and 5 p.m.


If after hours, please call 614-293-8000 (ask the operator to page the hospital administrative manager).

Latest News

Drug Harnesses Immune System To Combat Most Common Form of Lung Cancer

Recently approved immunotherapy drugs are offering patients – and their oncologists – new hope for extending survival of people with advanced non-small cell lung cancer (NSCLC).

Investigational Drug May Prevent Life-Threatening Muscle Loss in Advanced Cancers

New data describes how an experimental drug can stop life-threatening muscle wasting (cachexia) associated with advanced cancers and restore muscle health. The experimental agent, known as AR-42 while in...

One Day to Help Create More Healthy — And Cancer-Free — Tomorrows

Through the generous support of Don and Angie Ward, all donations made to Ohio State's cancer program today (Nov. 24) through Giving Tuesday (Dec. 1), will be matched, 100 percent, up to $50,000.